Third FDA orphan drug designation for ketamine granted to PharmaTher TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) for ketamine to treat Status…


Previous articlePsychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes
Next articleSmall Pharma Reports Fiscal Third Quarter 2021 Highlights